Literature DB >> 10814622

Measuring the costs and benefits of heart disease monitoring.

A Perry1, S Capewell, A Walker, J Chalmers, A Redpath, K Major, C E Morrison, N Craig, S Cobbe, W C Smith.   

Abstract

OBJECTIVE: To evaluate the costs and benefits of alternative systems of coronary heart disease monitoring in Scotland.
DESIGN: An option appraisal was conducted to evaluate the costs and benefits of implementing a coronary heart disease monitoring system. This involved a review of existing Scottish datasets and relevant reports, specification of options, definition and weighting of benefit criteria by key stakeholders, assessment of options by experts, and costing of options. The options were assessed by 33 stakeholders (grouped as cardiologists, patient representatives, general practitioners, public health physicians, and policy makers), plus 13 topic experts.
SETTING: Scotland (population 5.1 million).
RESULTS: Between group mean benefit weights were: mortality rates and case fatality (10.6), quality of life (9.8), patient function (8.8), hospital activity (7.8), primary care activity (9.25), prescribing (5.72), socioeconomic impact (4.0), risk factors (7.4), prevalence (5.0), incidence (6.0), case registration (6.82), international comparability (4.2), breadth of coverage (8.8), and frequency (5.8). Differences between group weights were significant for prevalence (p = 0.048) and international comparability (p = 0.032). Four monitoring options were identified: a community epidemiology model, based on MONICA (monitoring trends and determinants in cardiovascular disease) study methodology applied to a series of eight representative communities, had the highest benefits, at an average annual discounted cost of approximately pound 360,000; models based on the Australian cardiovascular disease monitoring scheme and on enhanced routine data offered fewer benefits at discounted average annual costs ranging from pound 165,000 to pound 195,000; finally, a coronary heart disease registry modelled on the Scottish Cancer Registry scheme would have had fewer benefits and substantially higher costs than the other options.
CONCLUSIONS: The most beneficial coronary heart disease monitoring system is the community epidemiology model, based on MONICA methodology. Option appraisal potentially offers an explicit and transparent methodology for evidence based policy development.

Entities:  

Mesh:

Year:  2000        PMID: 10814622      PMCID: PMC1760860          DOI: 10.1136/heart.83.6.651

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  8 in total

1.  Registering a need.

Authors:  L Donaldson
Journal:  BMJ       Date:  1992-09-12

2.  An approach to longitudinal studies in a community: the Framingham Study.

Authors:  T R DAWBER; W B KANNEL; L P LYELL
Journal:  Ann N Y Acad Sci       Date:  1963-05-22       Impact factor: 5.691

3.  Setting priorities: a framework for the assessment of health care priorities in Scottish Health Boards.

Authors:  D Breen
Journal:  Health Bull (Edinb)       Date:  1991-01

Review 4.  What value do computers provide to NHS hospitals?

Authors:  C Lock
Journal:  BMJ       Date:  1996-06-01

5.  The Pawtucket Heart Health Program: I. An experiment in population-based disease prevention.

Authors:  R A Carleton; T M Lasater; A Assaf; R C Lefebvre; S M McKinlay
Journal:  R I Med J       Date:  1987-12

6.  Design and analysis of community trials: lessons from the Minnesota Heart Health Program.

Authors:  D M Murray
Journal:  Am J Epidemiol       Date:  1995-09-15       Impact factor: 4.897

Review 7.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis.

Authors:  A Briggs; M Sculpher; M Buxton
Journal:  Health Econ       Date:  1994 Mar-Apr       Impact factor: 3.046

8.  The Stanford Five-City Project: design and methods.

Authors:  J W Farquhar; S P Fortmann; N Maccoby; W L Haskell; P T Williams; J A Flora; C B Taylor; B W Brown; D S Solomon; S B Hulley
Journal:  Am J Epidemiol       Date:  1985-08       Impact factor: 4.897

  8 in total
  1 in total

Review 1.  Global registries for measuring pharmacoeconomic and quality-of-life outcomes: focus on design and data collection, analysis and interpretation.

Authors:  Lisa Kennedy; Ann-Marie Craig
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.